With a focus on developing best-in-class precision medicines, KymaThera has closed an $80.0M Series B funding round. The capital infusion, backed by investors including Alta Partners, Venrock, Foresite Capital, and J. Wood Capital, will support the company's work in creating differentiated small-molecule therapeutics.
KymaThera's strength lies in its accomplished research team, which draws on decades of collective drug discovery experience and a proprietary framework for strategic structure-based drug design. This expertise has previously led to the discovery of multiple approved medicines for cancer and other serious diseases, aiming for better patient outcomes.
